LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.

    Castellano, Cecilia A / Sun, Tianyi / Ravindranathan, Deepak / Hwang, Clara / Balanchivadze, Nino / Singh, Sunny R K / Griffiths, Elizabeth A / Puzanov, Igor / Ruiz-Garcia, Erika / Vilar-Compte, Diana / Cárdenas-Delgado, Ana I / McKay, Rana R / Nonato, Taylor K / Ajmera, Archana / Yu, Peter P / Nadkarni, Rajani / O'Connor, Timothy E / Berg, Stephanie / Ma, Kim /
    Farmakiotis, Dimitrios / Vieira, Kendra / Arvanitis, Panos / Saliby, Renee M / Labaki, Chris / El Zarif, Talal / Wise-Draper, Trisha M / Zamulko, Olga / Li, Ningjing / Bodin, Brianne E / Accordino, Melissa K / Ingham, Matthew / Joshi, Monika / Polimera, Hyma V / Fecher, Leslie A / Friese, Christopher R / Yoon, James J / Mavromatis, Blanche H / Brown, Jacqueline T / Russell, Karen / Nanchal, Rahul / Singh, Harpreet / Tachiki, Lisa / Moria, Feras A / Nagaraj, Gayathri / Cortez, Kimberly / Abbasi, Saqib H / Wulff-Burchfield, Elizabeth M / Puc, Matthew / Weissmann, Lisa B / Bhatt, Padmanabh S / Mariano, Melissa G / Mishra, Sanjay / Halabi, Susan / Beeghly, Alicia / Warner, Jeremy L / French, Benjamin / Bilen, Mehmet A

    Cancer

    2024  

    Abstract: Background: COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes.: Methods: Using the COVID-19 and Cancer ... ...

    Abstract Background: COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes.
    Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, the authors identified 10,065 patients with COVID-19 and cancer (2325 with and 7740 without metastasis at the time of COVID-19 diagnosis). The primary ordinal outcome was COVID-19 severity: not hospitalized, hospitalized but did not receive supplemental O
    Results: Compared to patients without metastasis, patients with metastases have increased hospitalization rates (59% vs. 49%) and higher 30 day mortality (18% vs. 9%). Patients with metastasis to bone, lung, liver, lymph nodes, and brain have significantly higher COVID-19 severity (adjusted odds ratios [ORs], 1.38, 1.59, 1.38, 1.00, and 2.21) compared to patients without metastases at those sites. Patients with metastasis to the lung have significantly higher odds of 30-day mortality (adjusted OR, 1.53; 95% confidence interval, 1.17-2.00) when adjusting for COVID-19 severity.
    Conclusions: Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID-19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30-day mortality after COVID-19.
    Language English
    Publishing date 2024-02-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.35247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.

    Johnson, Douglas B / Atkins, Michael B / Hennessy, Cassandra / Wise-Draper, Trisha / Heilman, Hannah / Awosika, Joy / Bakouny, Ziad / Labaki, Chris / Saliby, Renee Maria / Hwang, Clara / Singh, Sunny R K / Balanchivadze, Nino / Friese, Christopher R / Fecher, Leslie A / Yoon, James J / Hayes-Lattin, Brandon / Bilen, Mehmet A / Castellano, Cecilia A / Lyman, Gary H /
    Tachiki, Lisa / Shah, Sumit A / Glover, Michael J / Flora, Daniel B / Wulff-Burchfield, Elizabeth / Kasi, Anup / Abbasi, Saqib H / Farmakiotis, Dimitrios / Viera, Kendra / Klein, Elizabeth J / Weissman, Lisa B / Jani, Chinmay / Puc, Matthew / Fahey, Catherine C / Reuben, Daniel Y / Mishra, Sanjay / Beeghly-Fadiel, Alicia / French, Benjamin / Warner, Jeremy L

    BMC cancer

    2023  Volume 23, Issue 1, Page(s) 265

    Abstract: Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity ... ...

    Abstract Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.
    Methods: Using the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors.
    Results: Of 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 - 1.39; targeted therapy OR 1.89, 95% CI 0.64 - 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 - 2.35).
    Conclusions: Melanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.
    MeSH term(s) Humans ; COVID-19/therapy ; Multiple Organ Failure ; Melanoma/complications ; Melanoma/therapy ; Immunotherapy
    Language English
    Publishing date 2023-03-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-023-10708-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top